de Haan L - Search Results

1

Genetic Risk and Outcome of Psychosis (GROUP), a multi-site longitudinal cohort study focused on gene-environment interaction: objectives, sample characteristics, recruitment and assessment methods.

Korver N, Quee PJ, Boos HB, Simons CJ, de Haan L; GROUP investigators. Korver N, et al. Among authors: de haan l. Int J Methods Psychiatr Res. 2012 Sep;21(3):205-21. doi: 10.1002/mpr.1352. Epub 2012 Mar 15. Int J Methods Psychiatr Res. 2012. PMID: 22419500 Free PMC article. Clinical Trial.

2

Olanzapine vs haloperidol for treatment of schizophrenia.

de Haan L, van Beveren N. de Haan L, et al. JAMA. 2004 Mar 3;291(9):1065; author reply 1065-6. doi: 10.1001/jama.291.9.1065-c. JAMA. 2004. PMID: 14996769 No abstract available.

3

Olanzapine and haloperidol for residual symptoms.

de Haan L, van Beveren N. de Haan L, et al. Am J Psychiatry. 2005 Jul;162(7):1392-3; author reply 1393. doi: 10.1176/appi.ajp.162.7.1392. Am J Psychiatry. 2005. PMID: 15994737 No abstract available.

4

Schizophrenia-associated neural growth factors in peripheral blood. A review.

van Beveren NJ, van der Spelt JJ, de Haan L, Fekkes D. van Beveren NJ, et al. Among authors: de haan l. Eur Neuropsychopharmacol. 2006 Oct;16(7):469-80. doi: 10.1016/j.euroneuro.2006.02.001. Epub 2006 Mar 20. Eur Neuropsychopharmacol. 2006. PMID: 16545550 Review.

5

The five-factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a revised model.

van der Gaag M, Hoffman T, Remijsen M, Hijman R, de Haan L, van Meijel B, van Harten PN, Valmaggia L, de Hert M, Cuijpers A, Wiersma D. van der Gaag M, et al. Among authors: de haan l, de hert m. Schizophr Res. 2006 Jul;85(1-3):280-7. doi: 10.1016/j.schres.2006.03.021. Epub 2006 May 26. Schizophr Res. 2006. PMID: 16730429

6

The five-factor model of the Positive and Negative Syndrome Scale I: confirmatory factor analysis fails to confirm 25 published five-factor solutions.

van der Gaag M, Cuijpers A, Hoffman T, Remijsen M, Hijman R, de Haan L, van Meijel B, van Harten PN, Valmaggia L, de Hert M, Wiersma D. van der Gaag M, et al. Among authors: de haan l, de hert m. Schizophr Res. 2006 Jul;85(1-3):273-9. doi: 10.1016/j.schres.2006.04.001. Epub 2006 May 26. Schizophr Res. 2006. PMID: 16730430

7

Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis.

van Nimwegen L, de Haan L, van Beveren N, Laan W, van den Brink W, Linszen D. van Nimwegen L, et al. Among authors: de haan l. J Clin Psychopharmacol. 2008 Apr;28(2):214-8. doi: 10.1097/JCP.0b013e318166f520. J Clin Psychopharmacol. 2008. PMID: 18344733 Clinical Trial.

8

Cessation of cannabis use by patients with recent-onset schizophrenia and related disorders.

Dekker N, de Haan L, van den Berg S, de Gier M, Becker H, Linzen DH. Dekker N, et al. Among authors: de haan l, de gier m. Psychopharmacol Bull. 2008;41(1):142-53. Psychopharmacol Bull. 2008. PMID: 18362877

9

Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial.

van Nimwegen LJ, de Haan L, van Beveren NJ, van der Helm M, van den Brink W, Linszen D. van Nimwegen LJ, et al. Among authors: de haan l. Can J Psychiatry. 2008 Jun;53(6):400-5. doi: 10.1177/070674370805300610. Can J Psychiatry. 2008. PMID: 18616861 Clinical Trial.

10

A visual metaphor describing neural dynamics in schizophrenia.

van Beveren NJ, de Haan L. van Beveren NJ, et al. Among authors: de haan l. PLoS One. 2008 Jul 9;3(7):e2577. doi: 10.1371/journal.pone.0002577. PLoS One. 2008. PMID: 18648540 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

893 results

Search Page